| 中文名称: | NSC23925 | ||||
|---|---|---|---|---|---|
| 英文名称: | NSC23925 | ||||
| 别名: | NSC23925 2-(p-Methoxyphenyl)-α-2-piperidyl-4-quinolinemethanol dihydrochloride, [2-(4-Methoxyphenyl)4-quinolinyl]-(piperidin-2-y)-methanol dihydrochloride | ||||
| CAS No: | 858474-14-3 | 分子式: | C22H26Cl2N2O2 | 分子量: | 421.36 |
| CAS No: | 858474-14-3 | ||||
| 分子式: | C22H26Cl2N2O2 | ||||
| 分子量: | 421.36 | ||||
基本信息
|
产品编号： |
N60016 |
||||
|
产品名称： |
NSC23925 |
||||
|
CAS: |
858474-14-3 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
|
||||
|
分子式： |
溶于液体 |
-80℃ |
6个月 |
||
|
分子量： |
421.36 |
-20℃ |
1个月 |
||
|
化学名： |
2-(p-Methoxyphenyl)-α-2-piperidyl-4-quinolinemethanol dihydrochloride,[2-(4-Methoxyphenyl)4-quinolinyl]-(piperidin-2-y)-methanol dihydrochloride |
||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
|
|||
|
Ethanol |
|
||||
|
Water |
|
||||
|
体内(现配现用): |
|
||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
2.3733mL |
11.8663mL |
23.7327mL |
|
5mM |
0.4747mL |
2.3733mL |
4.7465mL |
|
10mM |
0.2373mL |
1.1866mL |
2.3733mL |
生物活性
|
产品描述 |
一种新型的，有选择性且有效的P-糖蛋白(Pgp)抑制剂。 |
|
靶点 |
P-glycoprotein |
|
体外研究 |
NSC23925 is a novel,selective and effective P-glycoprotein (Pgp) inhibitor.SKOV-3 cells with long-term exposure of 1μM NSC23925 show stable growth in culture medium.NSC23925 specifically inhibits Pgp overexpression to prevent the emergence of paclitaxel resistance during paclitaxel treatment.NSC23925 reverses chemoresistance in a wide variety of tumor types where Multidrug resistance 1 (MDR1) is highly expressed. Maximal reversal of MDR is typically seen in NSC23925 doses between 0.5 and 1µM.The IC50 for NSC23925 is 8µM in SKOV-3/SKOV-3TR and 25µM in OVCAR8/OVCAR8TR cell lines,whereas the mean concentration of NSC23925 required for maximal reversal of resistance in SKOV-3TR or OVCAR8TR to cytotoxic drugs is 0.5µM to 1µM. |
|
体内研究 |
Both saline alone and NSC23925 alone treated tumors grow progressively.The usage of NSC23925 in paclitaxel chemotherapy significantly prolongs anticancer efficacy of paclitaxel. |
推荐实验方法(仅供参考)
|
细胞实验: |
|
|
To determine whether NSC23925 can prevent the emergence of paclitaxel resistance,paclitaxel resistant ovarian cancer cells are used.In brief,1×105 SKOV-3 cells are suspended in culture media containing paclitaxel alone,1μM NSC23925 alone,or paclitaxel in combination with 1μM NSC23925.When the cells are cultured to 90% confluence,1×105 cells are reseeded in a new tissue culture flask,and the paclitaxel dose is increased stepwise.The initial concentration of paclitaxel is 0.0001μM.At different selection points cell sublines are collected and stored at liquid nitrogen for further analysis. |
|
|
动物实验: |
|
|
Nude female mice at approximately 3 to 4 weeks of age are used.To evaluate the effects of NSC23925 on the induction of paclitaxel resistance in vivo,the paclitaxel resistant cells are established in human ovarian cancer xenograft models. Briefly,on day 1,approximately 2×106 parental sensitive SKOV-3 cells are injected subcutaneously with Matrigel into the flanks of 3 to 4-week-old female nude mice.Administration is initiated 12 days after injection of tumor cells.The mice are randomized into 4 groups and treated intraperitoneally with either saline alone,NSC23925 alone (50mg/kg),paclitaxel (25mg/kg) alone,or paclitaxel (25mg/kg) in combination with NSC23925 (50mg/kg) twice per week for 3 weeks followed by a treatment-free interval of 2 weeks.The second round of treatment is then continued.The size of tumors is recorded twice a week beginning on day 13.Tumor volume is measured with a digital caliper and calculated according to the formula (length×width2)/2. |
|
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
